Literature DB >> 20711577

¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.

Ashley M Groves1, Manu Shastry, Manuel Rodriguez-Justo, Anmol Malhotra, Raymondo Endozo, Timothy Davidson, Tina Kelleher, Kenneth A Miles, Peter J Ell, Mohammed R Keshtgar.   

Abstract

PURPOSE: Tumour angiogenesis is an independent and strong prognostic factor in early breast carcinoma. We performed this study to investigate the ability of (18)F-FDG to detect angiogenesis in early breast carcinoma using PET/CT.
METHODS: Twenty consecutive patients with early (T1-T2) breast carcinoma were recruited prospectively for 18F-FDG PET/CT. The PET/CT data were used to calculate whole tumour maximum standardized uptake value (SUV(max)) and mean standardized uptake value (SUV(mean)). All patients underwent subsequent surgery without prior chemotherapy or radiotherapy. The excised tumour underwent immunohistochemistry for vascular endothelial growth factor (VEGF), CD105 and glucose transporter protein 1 (GLUT1).
RESULTS: The SUV(max) showed the following correlation with tumour histology: CD105: r = 0.60, p = 0.005; GLUT1: r = 0.21, p = 0.373; VEGF: r = -0.16, p = 0.496. The SUV(mean) showed the following correlation with tumour histology: CD105: r = 0.65, p = 0.002; GLUT1: r = 0.34, p = 0.144; VEGF: r = -0.18, p = 0.443
CONCLUSION: (18)F-FDG uptake is highly significantly associated with angiogenesis as measured by the immunohistochemistry with CD105 for new vessel formation. Given that tumour angiogenesis is an important prognostic indicator and a predictor of treatment response, (18)F-FDG PET may have a role in the management of primary breast cancer patients even in early-stage disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20711577     DOI: 10.1007/s00259-010-1590-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  43 in total

1.  Standardized perfusion value: universal CT contrast enhancement scale that correlates with FDG PET in lung nodules.

Authors:  K A Miles; M R Griffiths; M A Fuentes
Journal:  Radiology       Date:  2001-08       Impact factor: 11.105

2.  Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography.

Authors:  Reinhard Bos; Jacobus J M van Der Hoeven; Elsken van Der Wall; Petra van Der Groep; Paul J van Diest; Emile F I Comans; Urvi Joshi; Gregg L Semenza; Otto S Hoekstra; Adriaan A Lammertsma; Carla F M Molthoff
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

Review 3.  Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis.

Authors:  S Sharma; M C Sharma; C Sarkar
Journal:  Histopathology       Date:  2005-05       Impact factor: 5.087

4.  Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis.

Authors:  S Kumar; A Ghellal; C Li; G Byrne; N Haboubi; J M Wang; N Bundred
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

Review 5.  Bevacizumab and breast cancer: current therapeutic progress and future perspectives.

Authors:  Sherry X Yang
Journal:  Expert Rev Anticancer Ther       Date:  2009-12       Impact factor: 4.512

6.  Vascular endothelial growth factor and endoglin expression in colorectal cancer.

Authors:  Konstantinos Dassoulas; Maria Gazouli; George Theodoropoulos; Zoi Christoni; Spyros Rizos; Adamantia Zisi-Serbetzoglou; Chrissa Glava; Theodoros Karantanos; Christos Klonaris; Petros Karakitsos
Journal:  J Cancer Res Clin Oncol       Date:  2009-11-05       Impact factor: 4.553

7.  Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer.

Authors:  David Groheux; Jean-Luc Moretti; Georges Baillet; Marc Espie; Sylvie Giacchetti; Elif Hindie; Christophe Hennequin; Jacques-Robert Vilcoq; Caroline Cuvier; Marie-Elisabeth Toubert; Jean-Emmanuel Filmont; Farid Sarandi; Jean-Louis Misset
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-23       Impact factor: 7.038

8.  Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy.

Authors:  David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Erin K Schubert; Jeffrey Tseng; Thomas J Lawton; Hannah M Linden; Robert B Livingston
Journal:  J Nucl Med       Date:  2003-11       Impact factor: 10.057

Review 9.  Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis.

Authors:  Bernard Uzzan; Patrick Nicolas; Michel Cucherat; Gérard-Yves Perret
Journal:  Cancer Res       Date:  2004-05-01       Impact factor: 12.701

10.  Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: correlation with long-term patient outcome.

Authors:  Jean-Philippe Dales; Stephane Garcia; Lucile Andrac; Severine Carpentier; Olivier Ramuz; Marie-Noëlle Lavaut; Claude Allasia; Pascal Bonnier; Colette Charpin
Journal:  Int J Oncol       Date:  2004-05       Impact factor: 5.650

View more
  26 in total

1.  Diagnostic and prognostic correlates of preoperative FDG PET for breast cancer.

Authors:  Vincent Vinh-Hung; Hendrik Everaert; Jan Lamote; Mia Voordeckers; Hilde van Parijs; Marian Vanhoeij; Guy Verfaillie; Christel Fontaine; Hansjoerg Vees; Osman Ratib; Georges Vlastos; Mark De Ridder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-10       Impact factor: 9.236

2.  Pretreatment PET in breast cancer: is there a role?

Authors:  Sue Chua; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12       Impact factor: 9.236

3.  PET/MRI and the revolution of the third eye.

Authors:  Luigi Mansi; Andrea Ciarmiello; Vincenzo Cuccurullo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10       Impact factor: 9.236

4.  Biodistribution and Internal Radiation Dosimetry of 99mTc-IDA-D-[c(RGDfK)]2 (BIK-505), a Novel SPECT Radiotracer for the Imaging of Integrin αvβ3 Expression.

Authors:  Yoo Sung Song; Joong Hyun Kim; Byung Chul Lee; Jae Ho Jung; Hyun Soo Park; Sang Eun Kim
Journal:  Cancer Biother Radiopharm       Date:  2018-08-22       Impact factor: 3.099

5.  Heterogeneity Analysis of (18)F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting.

Authors:  Hendra Budiawan; Gi Jeong Cheon; Hyung-Jun Im; Soo Jin Lee; Jin Chul Paeng; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2013-08-21

6.  Tumour 18 F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes.

Authors:  Jin You Kim; Suck Hong Lee; Suk Kim; Taewoo Kang; Young Tae Bae
Journal:  Eur Radiol       Date:  2014-10-09       Impact factor: 5.315

7.  Assessment of the metabolic flow phenotype of primary colorectal cancer: correlations with microvessel density are influenced by the histological scoring method.

Authors:  Vicky Goh; Manuel Rodriguez-Justo; Alec Engledow; Manu Shastry; Raymondo Endozo; Jacqui Peck; Marie Meagher; Stuart A Taylor; Steve Halligan; Ashley M Groves
Journal:  Eur Radiol       Date:  2012-04-18       Impact factor: 5.315

8.  Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.

Authors:  Marjan S Bolouri; Sjoerd G Elias; Dorota J Wisner; Spencer C Behr; Randall A Hawkins; Sachiko A Suzuki; Krysta S Banfield; Bonnie N Joe; Nola M Hylton
Journal:  Radiology       Date:  2013-07-22       Impact factor: 11.105

9.  Integrated 18F-fluorodeoxyglucose-positron emission tomography/dynamic contrast-enhanced computed tomography to phenotype non-small cell lung carcinoma.

Authors:  Manu Shastry; Kenneth A Miles; Thida Win; Sam M Janes; Raymond Endozo; Marie Meagher; Peter J Ell; Ashley M Groves
Journal:  Mol Imaging       Date:  2012 Sep-Oct       Impact factor: 4.488

10.  PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients.

Authors:  Irene A Burger; Hebert Alberto Vargas; Aditya Apte; Bradley J Beattie; John L Humm; Mithat Gonen; Steven M Larson; C Ross Schmidtlein
Journal:  Nucl Med Biol       Date:  2014-02-28       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.